Psychedelics Pharmaceutical company specializing in research, development and distribution of psychedelics PharmaTher Ther. (CSE: PHRM) (OTCQB: PHRRF) has filed for a provisional patent with the United States Patent and Trademark Office (USPTO) for the novel use of ketamine as a possible treatment for obesity and type 2 diabetes.
This was after the company evaluated its drug repurposing artificial intelligence (AI) platform, PanaceAI™.
The patent application is titled ‘Use of Ketamine in the Treatment of Diabetes and Obesity’. The study identifies protein binding and interactions with ketamine resulting to discovery of ketamine as a potential treatment of type 2 diabetes and obesity.
PharmaTher has already submitted an Investigational New Drug application to the U.S Food and Drug Administration (FDA) for commencement of a phase 2 clinical trial to evaluate ketamine in the treatment of Parkinson’s disease.
The company is also moving forward to advance research on panaceAI™ to evaluate repurposing opportunities with N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxy methamphetamine (MDMA) and lysergic acid diethylamide (LSD).
This advanced research will help in future clinical development and partnering opportunities.